DSSによる腸炎に対するブラウティア・プロダクタ1009924の緩和効果

Yishu Chen¹, Yan Ma², Yang Leng¹

¹Laboratory Animal Center, Guangdong Medical University, Zhanjiang, China.

Frontiers in microbiology

|August 27, 2025

まとめ

免疫反応を調節し,短鎖脂肪酸 (SCFA) の代謝を促進することで,ゼブラフィッシュの腸内炎症を効果的に軽減します. これは炎症性腸疾患 (IBD) の治療薬としての可能性を示唆しています.

科学分野:

微生物学
胃腸内科
免疫学

背景:

腸内細菌群は炎症性腸疾患 (IBD) の管理に不可欠です
IBDにおけるブラウティアプロダクトの役割は認められていますが,そのメカニズムはさらなる調査を必要としています.

研究の目的:

ブラウティアプロダクタ1009924の抗炎症効果を調査する.
IBDの治療の可能性を明らかにする.

主な方法:

1009924のブルーティアプロダクトを分離し,特徴づけました.
デクストラン硫酸ナトリウム (DSS) 誘発のゼブラフィッシュ腸炎モデルを確立した.
B. producta 1009924が炎症,免疫反応,腸内代謝に及ぼす影響を評価した.

主要な成果:

B. producta 1009924は,酸と胆塩に対する耐性を示し,代謝経路に富んだゲノムを持っています.
ゼブラフィッシュの腸内における活性酸素種 (ROS) と中性粒子の蓄積を抑制した.
この菌株は,DSSによる腸損傷を軽減し,TLR4/NF-κB経路を低下させ,有益な短鎖脂肪酸 (SCFA) を増加させた.

結論:

ブルーティア・プロダクタ1009924は,ゼブラフィッシュのモデルにおける腸炎症を有意に減少させる.
IBDの治療の可能性は,ROS,免疫応答,SCFA代謝の調節から生じる.

キーワード:

ブルーティー・プロダクト 1009924 ゲノム炎症性腸の炎症短鎖脂肪酸 (SCFA)

さらに関連する動画

08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.4K

08:39

Murine Colitis Modeling using Dextran Sulfate Sodium DSS

Published on: January 19, 2010

50.2K

関連する概念動画

01:17

Drugs for Treatment of Diarrhea-Predominant IBS

292

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

292

01:29

Drugs for Treatment of Ulcerative Colitis in IBD

236

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

236

01:21

Drugs for Treatment of Constipation-Predominant IBS

331

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

331

01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

419

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...

419

01:29

Inflammatory Bowel Disease IV: Pharmacological Management

189

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

189

01:17

Chronic Bowel Disorders: Introduction

540

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...

540

関連する実験動画